To address this, a group of small molecule inhibitors including those targeting EGFR (erlotinib, AG1478), PI3K (LY294002), Akt (MK2206), mTOR (rapamycin), Mek1/2 (PD0325901), NF‐κB (Bay 11–7082), Jak1/2 (ruxolitinib), and p38 (SB203580) was individually applied to treat PCa cells together with stromal AREG. This evidence concerns the gene NFKB1 and posterior cortical atrophy.